Drugs that missed the mark in pharma’s last earnings round

Drugs that missed the mark in pharma’s last earnings round is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kelly Bilodeau · 2026-08-11

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

Source: PharmaVoice